Conventional medical management of inflammatory bowel disease

Gastroenterology

Volumn 140, Issue 6, 2011, Pages 1827-1837.e2

  Burger, Daniel ^a   Travis, Simon ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Anti TNF Therapy; Corticosteroids; Crohn's Disease; Mesalamine; Treatment; Ulcerative Colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OLSALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; COLITIS; COLON RESECTION; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; ENTERITIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROCTITIS; ULCERATIVE COLITIS;

EID: 79955557278     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.02.045     Document Type: Article

References (97)

1. A. Kornbluth, and D.B. Sachar Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee Am J Gastroenterol 105 2010 501 523
2. S.P.L. Travis, E.F. Stange, and M. Lmann European evidence-based consensus on the management of ulcerative colitis: current management J Crohns Colitis 2 2008 24 62 (Pubitemid 351179488)
3. C.J. Ooi, K.M. Fock, and G.K. Makharia The Asia-Pacific consensus on ulcerative colitis J Gastroenterol Hepatol 25 2010 453 468
4. G.R. Lichtenstein, S.B. Hanauer, and W.J. Sandborn Management of Crohn's disease in adults Am J Gastroenterol 104 2009 465 483 quiz 464, 484
5. A. Dignass, G. Van Assche, and J.O. Lindsay The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management J Crohns Colitis 4 2010 28 62
6. S.C. Ng, and M.A. Kamm Therapeutic strategies for the management of ulcerative colitis Inflamm Bowel Dis 15 2009 935 950
7. G.R. Lichtenstein, and M.A. Kamm Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitismethods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa Aliment Pharmacol Ther 28 2008 663 673
8. J.M. Hebden, P.E. Blackshaw, and A.C. Perkins Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis Aliment Pharmacol Ther 14 2000 155 161 (Pubitemid 30088291)
9. P. Gionchetti, F. Rizzello, and A. Venturi Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis Aliment Pharmacol Ther 11 1997 1053 1057 (Pubitemid 27525110)
10. G. Bouguen, X. Roblin, and A. Bourreille Infliximab for refractory ulcerative proctitis Aliment Pharmacol Ther 31 2010 1178 1185
11. J.K. Marshall, M. Thabane, and A.H. Steinhart Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst Rev 2010 CD004115
12. M. Safdi, M. DeMicco, and C. Sninsky A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis Am J Gastroenterol 92 1997 1867 1871 (Pubitemid 27440908)
13. L. Sutherland, and J.K. Macdonald Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst Rev 2006 CD000543
14. P. Marteau, C.S. Probert, and S. Lindgren Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study Gut 54 2005 960 965 (Pubitemid 40873909)
15. T.R. Orchard, S.A. van der Geest, and S.P. Travis Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question Aliment Pharmacol Ther 2011 Mar 8 [Epub ahead of print]
16. W.A. Faubion Jr, E.V. Loftus Jr, and W.S. Harmsen The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study Gastroenterology 121 2001 255 260 (Pubitemid 32729372)
17. P. Rutgeerts, W.J. Sandborn, and B.G. Feagan Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476 (Pubitemid 41770166)
18. K. Ayre, B. Warren, and K. Jeffery The role of CMV in steroid-resistant ulcerative colitis: a systematic review J Crohns Colitis 3 2009 141 148
19. G.C. Nguyen, G.G. Kaplan, and M.L. Harris A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients Am J Gastroenterol 103 2008 1443 1450 (Pubitemid 351813903)
20. D. Turner, C.M. Walsh, and A.H. Steinhart Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression Clin Gastroenterol Hepatol 5 2007 103 110 (Pubitemid 46096828)
21. S.P.L. Travis, J. Satsangi, and M. Lmann Predicting the need for colectomy in severe UC: a critical appraisal of clinical parameters and currently available biomarkers Gut 60 2011 3 9
22. D. Laharie, A. Bourreille, and J. Branche Ciclospirin and infliximab for acute severe colitis failing intravenous steroids: a randomised controlled trial J Crohns Colitis 5 2011 S8
23. G.G. Jarnerot, E.E. Hertervig, and I.I. Friis-Liby Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study Gastroenterology 128 2005 1805 1811
24. A. Gustavsson, G. Jarnerot, and E. Hertervig Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study Aliment Pharmacol Ther 32 2010 984 989
25. G. Van Assche, G. D'Haens, and M. Noman Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis Gastroenterology 125 2003 1025 1031 (Pubitemid 37193449)
26. C.W. Lees, D. Heys, and G.T. Ho A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis Aliment Pharmacol Ther 26 2007 411 419 (Pubitemid 47063146)
27. M. Ferrante, A. D'Hoore, and S. Vermeire Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis Inflamm Bowel Dis 15 2009 1062 1070
28. G.C. Nguyen, and C.M. Prather Is keeping the colon the ultimate marker of success in ulcerative colitis? Gastroenterology 137 2009 1204 1206
29. J.P. Gisbert, P. Nino, and C. Cara Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients Aliment Pharmacol Ther 28 2008 228 238 (Pubitemid 351861969)
30. M.M. Lawson, A.G. Thomas, and A.K. Akobeng Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis Cochrane Database Syst Rev 3 2006 CD005112
31. A. Oussalah, L. Evesque, and D. Laharie A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization Am J Gastroenterol 105 2010 2617 2625
32. W. Reinisch, W.J. Sandborn, and D. Hommes Adalimumab for induction of remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial Gut 2011 Jan 5 [Epub ahead of print]
33. S. Travis Does it all ADA up? Adalimumab for ulcerative colitis Gut 2011 Jan 21 [Epub ahead of print]
34. I.C. Solberg, M.H. Vatn, and O. Hoie Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study Clin Gastroenterol Hepatol 5 2007 1430 1438 (Pubitemid 350181602)
35. C. Loly, J. Belaiche, and E. Louis Predictors of severe Crohn's disease Scand J Gastroenterol 43 2008 948 954
36. G. D'Haens, R. Panaccione, and P.D. Higgins The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: when to start, when to stop, which drug to choose and how to predict response? Am J Gastroenterol 106 2011 199 212
37. S.B. Hanauer, and U. Strmberg Oral pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials Clin Gastroenterol Hepatol 2 2004 379 388 (Pubitemid 38561234)
38. A. Tromm, I. Bunganic, and E. Tomsova Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease Gastroenterology 140 2011 425 434
39. C.H. Seow, E.I. Benchimol, and A.M. Griffiths Budesonide for induction of remission in Crohn's disease Cochrane Database Syst Rev 2008 CD000296
40. B.G. Feagan, J. Rochon, and R.N. Fedorak Methotrexate for the treatment of Crohn's disease The North American Crohn's Study Group Investigators N Engl J Med 332 1995 292 297
41. A.A. Alfadhli, J.W. McDonald, and B.G. Feagan Methotrexate for induction of remission in refractory Crohn's disease Cochrane Database Syst Rev 2005 CD003459
42. G. Van Assche, J.D. Lewis, and G.R. Lichtenstein The London Position Statement of the World Congress of Gastroenterology on the biological therapy for IBD with the European Crohn's and Colitis Organisation: Safety Am J Gastroenterol 106 2011 214 223
43. L. Peyrin-Biroulet, P. Deltenre, and N. de Suray Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials Clin Gastroenterol Hepatol 6 2008 644 653 (Pubitemid 351783447)
44. F. Schnitzler, H. Fidder, and M. Ferrante Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort Gut 58 2009 492 500
45. G.R. Lichtenstein, A. Olson, and S. Travers Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease Am J Gastroenterol 101 2006 1030 1038 (Pubitemid 43725317)
46. K. Vagianos, S. Bector, and J. McConnell Nutrition assessment of patients with inflammatory bowel disease JPEN J Parenter Enteral Nutr 31 2007 311 339
47. D.R. van Langenberg, K. Lange, and D.J. Hetzel Adverse clinical phenotype in inflammatory bowel disease: a cross sectional study identifying factors potentially amenable to change J Gastroenterol Hepatol 25 2010 1250 1258
48. T. Jess, L. Riis, and I. Vind Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark Inflamm Bowel Dis 13 2007 481 489 (Pubitemid 46668255)
49. L. Sutherland, and J.K. Macdonald Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis Cochrane Database Syst Rev 2006 CD000544
50. J.K. Marshall, and E.J. Irvine Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis Aliment Pharmacol Ther 9 1995 293 300
51. G.A. Moody, J.A. Eaden, and Z. Helyes Oral or rectal administration of drugs in IBD? Aliment Pharmacol Ther 11 1997 999 1000 (Pubitemid 27445691)
52. G. d'Albasio, F. Pacini, and E. Camarri Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study Am J Gastroenterol 92 1997 1143 1147 (Pubitemid 27304810)
53. O.A. Paoluzi, F. Iacopini, and R. Pica Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study Aliment Pharmacol Ther 21 2005 1111 1119 (Pubitemid 40646537)
54. W. Kruis, L. Jonaitis, and J. Pokrotnieks Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis Aliment Pharmacol Ther 33 2011 313 322
55. M.A. Kamm, G.R. Lichtenstein, and W.J. Sandborn Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis Gut 57 2008 893 902 (Pubitemid 351919522)
56. A. Bitton, M.A. Peppercorn, and D.A. Antonioli Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis Gastroenterology 120 2001 13 20 (Pubitemid 32061864)
57. F.S. Velayos, E.V. Loftus Jr, and T. Jess Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study Gastroenterology 130 2006 1941 1949 (Pubitemid 43816957)
58. T.P. van Staa, T. Card, and R.F. Logan 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study Gut 54 2005 1573 1578 (Pubitemid 41531774)
59. J.P. Gisbert, P.M. Linares, and A.G. McNicholl Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis Aliment Pharmacol Ther 30 2009 126 137
60. S. Ardizzone, G. Maconi, and A. Russo Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis Gut 55 2006 47 53 (Pubitemid 41820634)
61. W.J. Sandborn, P. Rutgeerts, and B.G. Feagan Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab Gastroenterology 137 2009 1250 1260
62. J.F. Colombel, P. Rutgeerts, and W. Reinisch Mucosal healing in patients with ulcerative colitis associates with a reduced colectomy risk, high incidence of symptomatic remission and corticosteroid-free state Abstract P1511 Gut 59 2010 A411
63. J. Cosnes, F. Carbonnel, and L. Beaugerie Effects of cigarette smoking on the long-term course of Crohn's disease Gastroenterology 110 1996 424 431 (Pubitemid 26043875)
64. A.K. Akobeng, and E. Gardener Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease Cochrane Database Syst Rev 2005 CD003715
65. A.H. Steinhart, A. Forbes, and E.C. Mills Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease Aliment Pharmacol Ther 25 2007 1389 1399 (Pubitemid 46848885)
66. E.I. Benchimol, C.H. Seow, and A.R. Otley Budesonide for maintenance of remission in Crohn's disease Cochrane Database Syst Rev 2009 CD002913
67. E. Prefontaine, J.K. Macdonald, and L.R. Sutherland Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease Cochrane Database Syst Rev 6 2010 CD000545
68. B.G. Feagan, R.N. Fedorak, and E.J. Irvine A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease North American Crohn's Study Group Investigators N Engl J Med 342 2000 1627 1632 (Pubitemid 30341531)
69. B.W. Behm, and S.J. Bickston Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease Cochrane Database Syst Rev 2008 CD006893
70. J.F.J. Colombel, W.J.W. Sandborn, and W.W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
71. R. Panaccione, J.F. Colombel, and W.J. Sandborn Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease Aliment Pharmacol Ther 31 2010 1296 1309
72. B. Feagan, J.W. McDonald, and R. Panaccione A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease Gastroenterology 135 2008 294 295
73. L. Peyrin-Biroulet, E.V. Loftus Jr, and J.F. Colombel The natural history of adult Crohn's disease in population-based cohorts Am J Gastroenterol 105 2010 289 297
74. G.E. Reese, T. Nanidis, and C. Borysiewicz The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies Int J Colorectal Dis 23 2008 1213 1221
75. G. Doherty, G. Bennett, and S. Patil Interventions for prevention of post-operative recurrence of Crohn's disease Cochrane Database Syst Rev 2009 CD006873
76. M. Regueiro, W. Schraut, and L. Baidoo Infliximab prevents Crohn's disease recurrence after ileal resection Gastroenterology 136 2009 441 450.e1
77. K.T. Thia, U. Mahadevan, and B.G. Feagan Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study Inflamm Bowel Dis 15 2009 17 24
78. B.E.B. Sands, F.H.F. Anderson, and C.N.C. Bernstein Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 2004 876 885
79. R.L. West, C.J. van der Woude, and B.E. Hansen Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study Aliment Pharmacol Ther 20 2004 1329 1336 (Pubitemid 40040080)
80. D. Tougeron, G. Savoye, and C. Savoye-Collet Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease Dig Dis Sci 54 2009 1746 1752
81. J.F. Colombel, D.A. Schwartz, and W.J. Sandborn Adalimumab for the treatment of fistulas in patients with Crohn's disease Gut 58 2009 940 948
82. S. Lichtiger, D.G. Binion, and D.C. Wolf The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy Aliment Pharmacol Ther 32 2010 1228 1239
83. S. Kane, D. Huo, and J. Aikens Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis Am J Med 114 2003 39 43 (Pubitemid 36126514)
84. P. Rutgeerts, R.H. Diamond, and M. Bala Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease Gastrointest Endosc 63 2006 433 442 (Pubitemid 43261469)
85. J.J.-F. Colombel, W.J.W. Sandborn, and P.P. Rutgeerts Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 2007 52 65
86. W.J. Sandborn, S. Schreiber, and S.B. Hanauer Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study Clin Gastroenterol Hepatol 8 2010 696 702 e1
87. W.J. Sandborn, P. Rutgeerts, and R. Enns Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial Ann Intern Med 146 2007 829 838 (Pubitemid 351650483)
88. W.J. Sandborn, M.T. Abreu, and G. D'Haens Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab Clin Gastroenterol Hepatol 8 2010 688 695 e2
89. M. Allez, S. Vermeire, and N. Mozziconacci The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies Aliment Pharmacol Ther 31 2010 92 101
90. S.R. Targan, B.G. Feagan, and R.N. Fedorak Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial Gastroenterology 132 2007 1672 1683 (Pubitemid 46695722)
91. X. Treton, Y. Bouhnik, and J.Y. Mary Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse Clin Gastroenterol Hepatol 7 2009 80 85
92. E. Louis, G. Vernier-Massouille, and J.-C. Grimaud 961 Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study Gastroenterology 136 2009 A-146
93. J.F. Colombel, W.J. Sandborn, and R. Panaccione Adalimumab safety in global clinical trials of patients with Crohn's disease Inflamm Bowel Dis 15 2009 1308 1319
94. C. Canavan, K.R. Abrams, and J.F. Mayberry Meta-analysis: mortality in Crohn's disease Aliment Pharmacol Ther 25 2007 861 870 (Pubitemid 46525338)
95. A.V. Ramadas, S. Gunesh, and G.A. Thomas Natural history of Crohn's disease in a population-based cohort from Cardiff (19862003): a study of changes in medical treatment and surgical resection rates Gut 59 2010 1200 1206
96. F. Baert, L. Moortgat, and G. Van Assche Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease Gastroenterology 138 2010 463 468
97. B. Pariente, J. Cosnes, and S. Danese Development of the Lemann Crohn's Disease Digestive Damage Score (CD3S) Inflamm Bowel Dis 2010 Nov 28 [Epub ahead of print]